Claims

1. Use of PIC in the manufacture of a medicament for use in a method of treatment of cancer and cancer-induced malignant effusion, for administration of the medicament to the mucosa of the subject.

2. The use according to claim 1, wherein the medicament comprises PIC and at least one stabilising agent.

3. The use according to claim 2, wherein the stabilising agent is selected from the group consisting of kanamycin, poly-lysine, protamine, chitin, chitosan, spermine and glucosamine.

4. The use according to claim 2, wherein the stabilising agent is Kanamycin.

5. The use according to claim 4, wherein the medicament comprises 500 to 10000 µg PIC per unit dose and 500 to 10000 IU kanamycin per unit dose.

6. The use according to claims 1 to 5, wherein the medicament further comprises calcium chloride.

7. The use according to claim 6, wherein the amount of calcium chloride is 0.1 to 5.0 mmol per unit dose.

8. The use according to claims 1 to 7, wherein the method is for treatment of a cancer-induced malignant effusion.

9. The use according to claims 1 to 8, wherein the mucosa is lung mucosa, intestinal mucosa or airway mucosa.

10. The use according to claims 1 to 9, wherein the ratio of polyinosinic acid and polycytidylic acid is selected from the group consisting of 0.8:1.0, 0.9:1.0, 1.0:1.0, 1.0:1.1, 1.0:1.2.

11. The use according to claims 1 to 10, wherein the medicament is a liquid or fluid formulation in which a unit dose is provided in a volume of the liquid or fluid between 0.1 ml and 10.0 ml.

12. The use according to claims 1 to 11, wherein the medicament further comprises an antigen.

13. The use according to claim 12, wherein the source of antigen is a human, non-human animal, plant, bacteria, fungus, virus, parasite or cancer antigen.

14. The use according to claims 1 to 13, wherein the medicament acts as an adjuvant in enhancing immunogenic responses in the subject host against virus, bacteria, fungus, parasite or cancer.

15. The use according to claims 1 to 14, wherein the medicament is delivered or administered vaginally, rectally, intranasally, intragastrically, enterally, ocularly, orally, by inhalation, opthamalically, topically, pulmonary, or transdermally.

16. The use according to claims 1 to 15, wherein the medicament is to be delivered or administered by inhalation, e.g. via the assistance of inhaler, spray, applicator or nebulizer.

17. The use according to claims 1 to 16, wherein the medicament is to be delivered or administered 5 times per day, 4 times per day, 3 times per day, twice per day, once per day, on alternative days, 6 times per week, 5 times per week, 4 times per week, 3 times per week, twice per week, weekly, four times per month, 3 times per month, twice per month, monthly, or bimonthly.

18. The use according to claims 1 to 17, wherein the medicament is to be delivered or administered in conjunction with another administration of the medicament by a route selected from the group consisting of intradermal injection, intramuscular injection, subcutaneous injection, intravenous infusion, intraperitoneal perfusion, intrapleural perfusion, intrapericardial injection.

19. The use according to claims 1 to 18, wherein the medicament is to be delivered or administered by systemic administration and by mucosal delivery or administration.

20. The use according to claims 1 to 19, wherein the medicament is to be administered during and/or via an intestinal intubation, gastric intubation, chest drainage, thoracentesis, temporary or permanent pleural catheter insertion, thoracoscopic pleurodesis, pericardial intraluminal stenting or fenestrated drainage, or surgical shunting procedure.

21. The use according to claims 1 to 20, wherein the medicament is effective in controlling cancerous growth and reducing tumor size at the site of deposition and/or remote site of deposition.

22. The use according to claims 1 to 21, wherein the medicament is effective in controlling cancer-induced malignant effusion.

23. The use according to claims 1 to 22, wherein the use further comprises a therapeutically effective amount of radiation targeted against the underlying cancer to be administered together with the medicament.

24. The use according to claim 23, wherein the radiation is to be given before, after or during the administration of the medicament.